GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Zevra Therapeutics
Zevra Therapeutics is a biopharmaceutical company specializing in the treatment of rare diseases. Its stock price is tied to the commercialization of its drugs and progress in clinical trials, a typical model for niche biotech companies.
Share prices of companies in the market segment - Pharma neurology
Zevra Therapeutics is a pharmaceutical company specializing in the development and commercialization of treatments for rare diseases with a focus on the central nervous system and metabolism. We classify it as "Pharmaceuticals (Neurology)." The chart below illustrates the dynamics of this complex medical segment.
Broad Market Index - GURU.Markets
Zevra Therapeutics is a pharmaceutical company specializing in developing drugs for the treatment of rare diseases of the central nervous system. As a significant player, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Zevra's performance to assess the state of the sector.
Change in the price of a company, segment, and market as a whole per day
ZVRA - Daily change in the company's share price Zevra Therapeutics
The daily price change of Zevra Therapeutics, a company specializing in rare CNS diseases, reflects the high risks of the biotech sector. Change_co is an instant reaction to research news. This indicator is the basis for pharmaceutical sector analysis on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma neurology
Zevra Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with ZVRA, which focuses on rare diseases, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Zevra is a biopharmaceutical company specializing in drugs for rare diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Zevra's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Zevra Therapeutics
Zevra Therapeutics' year-over-year performance reflects its strategy to commercialize drugs for rare CNS diseases. Its 12-month market cap reflects progress in obtaining FDA approvals and commercializing products targeting small but underserved patient populations, providing the company with a market niche.
Annual dynamics of market capitalization of the market segment - Pharma neurology
Zevra Therapeutics, Inc. is a pharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare diseases. The chart shows how its success in bringing drugs to market and clinical trial results impacts its performance relative to the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Zevra Therapeutics is a biopharmaceutical company whose stock performance is driven by the commercialization of its products for rare diseases and progress in research. The company's business is not dependent on economic cycles. This chart reflects biotech events, not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Zevra Therapeutics
Zevra, a pharmaceutical company, is driven by its product cycle. Monthly fluctuations on the chart reflect news related to FDA approvals and commercial launches of its rare disease drugs, the success of which determines its future.
Monthly dynamics of market capitalization of the market segment - Pharma neurology
Zevra Therapeutics is a pharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare diseases, primarily in neuroscience. The chart below illustrates the overall dynamics of the biotech sector, where focusing on orphan diseases is a proven business model.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Zevra Therapeutics is a pharmaceutical company specializing in rare diseases. Its value is determined by its pipeline of drugs and the commercial potential of its approved products. The company's shares are driven by FDA news and trial data, rather than by overall market conditions.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Zevra Therapeutics
Zevra Therapeutics is a biopharmaceutical company specializing in rare diseases of the central nervous system. Its weekly stock price is volatile and depends on progress in drug development, FDA decisions, and partnership news.
Weekly dynamics of market capitalization of the market segment - Pharma neurology
Zevra, like the entire rare disease biotech sector, is extremely volatile. Weekly stock price movements in this segment often reflect broader scientific breakthroughs that influence investor interest in the entire sector. The chart illustrates this sectoral relationship.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Zevra Therapeutics is a biopharmaceutical company focused on rare diseases. Its shares are immersed in clinical trial news. The chart clearly shows how the company's weekly performance is detached from the broader market, moving along its own unique trajectory.
Market capitalization of the company, segment and market as a whole
ZVRA - Market capitalization of the company Zevra Therapeutics
Zevra Therapeutics' market capitalization is a bet on developing drugs for rare diseases. This pharmaceutical company's chart shows how the market values its portfolio of drugs targeting small patient groups with high unmet medical needs.
ZVRA - Share of the company's market capitalization Zevra Therapeutics within the market segment - Pharma neurology
Zevra Therapeutics is a biopharmaceutical company that builds market share by focusing on the development and commercialization of drugs for rare diseases, often through acquisitions of assets from other companies.
Market capitalization of the market segment - Pharma neurology
Zevra Therapeutics focuses on rare diseases. How big is this niche? The chart below shows the overall market capitalization of the neuroscience pharmaceutical sector. Its growth reflects how biotech companies are finding significant opportunities in helping small, previously neglected patient populations.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Zevra Therapeutics chart is a visualization of its rare disease drug development strategy. The company's market cap is a bet on the success of its drugs for sleep and metabolic disorders. This diagram illustrates how focusing on orphan diseases can generate significant value if successful.
Book value capitalization of the company, segment and market as a whole
ZVRA - Book value capitalization of the company Zevra Therapeutics
For Zevra Therapeutics, which specializes in rare CNS diseases, book value is its tangible assets: R&D assets, drug rights, and financial reserves for completing clinical trials. The chart below shows how this scientific and financial foundation was formed.
ZVRA - Share of the company's book capitalization Zevra Therapeutics within the market segment - Pharma neurology
Zevra Therapeutics is a biopharmaceutical company focused on rare diseases. Its tangible assets include research laboratories and partner manufacturing facilities for the development of unique drugs. The chart shows the share of this specialized R&D and manufacturing infrastructure the company controls.
Market segment balance sheet capitalization - Pharma neurology
Zevra Therapeutics is a biopharmaceutical company. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. Zevra focuses on drug development, and its capital is its intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Zevra Therapeutics' balance sheet represents its laboratories and R&D capabilities for developing drugs for rare diseases. The chart shows how the company built its scientific and material foundation to address complex medical problems.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Zevra Therapeutics
Zevra Therapeutics is a biotech company. Its market valuation is a bet on its ability to successfully commercialize drugs for rare diseases. The chart shows how this investor belief has evolved.
Market to book capitalization ratio in a market segment - Pharma neurology
Zevra Therapeutics is a biopharmaceutical company specializing in rare diseases. Its valuation depends on the success of its drugs and clinical development. The chart shows how its market capitalization, based on expectations, relates to its assets.
Market to book capitalization ratio for the market as a whole
Zevra Therapeutics is a biopharmaceutical company specializing in developing drugs for rare diseases. Its current valuation, compared to the average, is a bet on the success of its drugs. Investors evaluate the potential of its developments to address unmet medical needs, which is unrelated to its current tangible assets.
Debts of the company, segment and market as a whole
ZVRA - Company debts Zevra Therapeutics
Zevra Therapeutics is a biopharmaceutical company focused on treating rare diseases. This chart illustrates its financial strategy. The company uses capital raised from investors and partners to advance its drug candidates through clinical trials and the regulatory approval process, which requires significant and risky investments.
Market segment debts - Pharma neurology
Zevra Therapeutics is a biopharmaceutical company focused on developing drugs for rare diseases, particularly in neuroscience. The company's debt policy reflects its need for capital to conduct clinical trials and bring niche products to market. This chart shows how Zevra is funding its path into the highly specialized orphan disease sector.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Zevra Therapeutics
Zevra Therapeutics is a biopharmaceutical company specializing in rare diseases. Developing and bringing such drugs to market is a lengthy and costly process. This chart shows the company's reliance on debt to fund its research and development. It is a key indicator of its financial risk and viability.
Market segment debt to market segment book capitalization - Pharma neurology
Zevra Therapeutics is a pharmaceutical company specializing in the treatment of rare diseases. This chart shows the debt burden in the biotech sector. It is an indicator of the company's ability to finance its clinical trials and the commercialization of drugs for patients with limited therapeutic options.
Debt to book value of all companies in the market
Zevra Therapeutics is a biopharmaceutical company specializing in rare diseases. Developing orphan drugs requires significant, but risky, investment. This chart of total market debt demonstrates how favorable the financial environment is overall for raising capital for companies with long-term and unpredictable research cycles.
P/E of the company, segment and market as a whole
P/E - Zevra Therapeutics
Zevra Therapeutics is a biopharmaceutical company specializing in developing treatments for rare diseases, primarily neurological ones. This chart reflects investor expectations for this niche pharmaceutical company. Its performance depends on clinical trial success and regulatory approvals for its orphan drugs.
P/E of the market segment - Pharma neurology
Zevra Therapeutics is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of rare diseases, primarily in neurology and cardiology. This chart shows the average valuation for the pharmaceutical sector, reflecting investor interest in companies operating in the orphan (rare) disease market.
P/E of the market as a whole
Zevra Therapeutics is a biopharmaceutical company specializing in developing treatments for rare diseases. Its valuation is entirely dependent on the success of its drugs and clinical trial data. Overall market sentiment, reflected in this chart, has virtually no bearing on the company's performance. Zevra's fate is being decided in laboratories and doctors' offices.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Zevra Therapeutics
Zevra Therapeutics is a biopharmaceutical company specializing in developing treatments for rare diseases, primarily in neuroscience. This chart reflects expectations for its clinical programs. The company's valuation is based on the approval and commercial success of its drugs for patients with orphan diseases.
%20P%2FE%20Zevra%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Zevra-Therapeutics&v=1772661065734 "Chart of the company's future (projected) P/E Zevra Therapeutics")
Future (projected) P/E of the market segment - Pharma neurology
Zevra Therapeutics is a biopharmaceutical company specializing in developing treatments for rare diseases, particularly in neuroscience. This chart reflects speculative expectations for its clinical programs. Comparing these forecasts with the sector reveals the level of investor confidence in its scientific potential and ability to bring new drugs to market.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-neurology&v=1772661065751 "Future (projected) P/E graph of the market segment - Pharma neurology")
Future (projected) P/E of the market as a whole
Zevra Therapeutics is a biopharmaceutical company specializing in developing drugs for rare diseases, particularly in neuroscience. Its value depends on the success of clinical trials. This general risk appetite chart determines how willing investors are to invest in risky biotech companies with long profit horizons.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772661065782 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Zevra Therapeutics
Zevra Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly in neuroscience. Its financial performance depends on successful sales of existing products and the advancement of new candidates through clinical trials. This chart shows the company's development path in the orphan drug niche.
Profit of companies in the market segment - Pharma neurology
Zevra Therapeutics is a biopharmaceutical company specializing in developing treatments for rare diseases, particularly in neurology. Its focus on orphan diseases allows it to occupy unique market niches. The profitability chart for its sector demonstrates the success of the rare disease-focused business model and how regulators incentivize such developments.
Overall market profit
Zevra Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, particularly in neuroscience. Such companies play a critical role, as these niches are often overlooked by larger players. Zevra's success depends on scientific breakthroughs and could bring hope to patients with orphan diseases.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Zevra Therapeutics
Zevra Therapeutics specializes in developing drugs for rare diseases of the central nervous system. This chart reflects speculative expectations for its clinical pipeline. Future revenue is entirely dependent on the approval and commercialization of its drug candidates.
%20profit%20of%20the%20company%20Zevra%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Zevra-Therapeutics&v=1772661065812 "Graph of future (projected) profit of the company Zevra Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma neurology
Zevra Therapeutics is a pharmaceutical company specializing in developing treatments for rare diseases, particularly in neurology. The data in the chart shows profit projections for the pharmaceutical industry. This allows us to assess the extent to which focusing on orphan diseases can be a successful strategy within the overall biotech industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-neurology&v=1772661065829 "Graph of future (predicted) profits of companies in a market segment - Pharma neurology")
Future (predicted) profit of the market as a whole
The profit outlook for Zevra Therapeutics, a pharmaceutical company focused on rare diseases, depends on the successful commercialization of its products and regulatory approval of new drugs. This chart reflects investor expectations for its niche strategy, which could lead to high drug prices despite proven efficacy.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772661065836 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Zevra Therapeutics
Zevra Therapeutics specializes in developing drugs for rare diseases, particularly in neurology. The company may not have stable revenue. This chart shows its valuation based on the potential value of its drug candidates, which could receive orphan drug designation.
P/S market segment - Pharma neurology
Zevra Therapeutics is a biopharmaceutical company specializing in developing treatments for rare diseases, particularly in neuroscience. Its valuation is based on the potential of its drugs. This chart shows the average valuation in the biotech sector, reflecting investor expectations for Zevra's future revenue if its developments are commercially successful.
P/S of the market as a whole
Zevra Therapeutics is a biopharmaceutical company specializing in developing treatments for rare diseases, particularly in neuroscience. Its valuation is dependent on the success of its clinical programs. This chart, showing Zevra's average revenue estimate, highlights that early-stage biotechs prioritize scientific potential and addressable market size over revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Zevra Therapeutics
Zevra Therapeutics is a biopharmaceutical company specializing in developing treatments for rare diseases, particularly in neurology. This chart reflects investor expectations for its developments. It shows the market's assessment of the likelihood of clinical trial success and the commercial potential of its drugs in niche markets.
%20P%2FS%20Zevra%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Zevra-Therapeutics&v=1772661065899 "The graph of the company's future (projected) P/S Zevra Therapeutics")
Future (projected) P/S of the market segment - Pharma neurology
Zevra Therapeutics is a biopharmaceutical company specializing in developing treatments for rare diseases of the central nervous system. This chart compares market expectations for its future revenue with other neuroscience pharmaceutical companies. This valuation reflects investor confidence in its product portfolio and its ability to bring drugs to market.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-neurology&v=1772661065922 "Future (projected) P/S market segment graph - Pharma neurology")
Future (projected) P/S of the market as a whole
Zevra Therapeutics is a biopharmaceutical company specializing in the treatment of rare diseases of the central nervous system. Its future depends on the approval and commercialization of its drugs. Zevra's potential to offer solutions for patients with unmet medical needs is part of the overall optimism surrounding medical innovation.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772661065944 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Zevra Therapeutics
Zevra Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, primarily in neurology. While in clinical trials, it may not have stable revenue. This chart shows revenue from future sales or partnerships.
Sales of companies in the market segment - Pharma neurology
Zevra Therapeutics is a biopharmaceutical company specializing in developing treatments for rare diseases of the central nervous system. Its approach is aimed at solving problems for which there are few or no therapeutic options. This chart shows overall sales in the pharmaceutical sector, illustrating the potential and complexity of bringing drugs for orphan diseases to market.
Overall market sales
Zevra Therapeutics is a biopharmaceutical company specializing in developing treatments for rare diseases, particularly in neuroscience. This overall economic climate impacts Zevra through the investment climate. Funding for orphan disease development is highly dependent on capital availability and investor interest.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Zevra Therapeutics
Zevra Therapeutics is a biopharmaceutical company specializing in developing treatments for rare diseases, particularly in neurology. Future revenues are dependent on the success of its clinical programs and regulatory approvals. This chart reflects analyst expectations for the commercial potential of its drugs in niche but important markets.
%20sales%20of%20the%20company%20Zevra%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Zevra-Therapeutics&v=1772661066023 "Schedule of future (projected) sales of the company Zevra Therapeutics")
Future (projected) sales of companies in the market segment - Pharma neurology
Zevra Therapeutics is a biopharmaceutical company specializing in developing drugs for rare diseases, particularly in neuroscience. This chart shows projected revenues for the entire pharmaceutical sector. While it provides a general overview, Zevra's success depends on clinical results and the commercialization of its niche drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-neurology&v=1772661066025 "Schedule of future (projected) sales of companies in the market segment - Pharma neurology")
Future (projected) sales of the market as a whole
Zevra Therapeutics is a biopharmaceutical company specializing in the treatment of rare diseases. Its success depends on the approval and commercialization of its drugs. This schedule, reflecting the state of the economy, affects the ability of healthcare systems and insurance companies to cover expensive treatments for rare diseases, which is key to Zevra's long-term profitability.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772661066040 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Zevra Therapeutics
Zevra Therapeutics is a pharmaceutical company focused on rare diseases. This chart shows its financial trajectory. Profitability in this niche depends on the ability to successfully advance drugs through clinical trials and set high prices for approved drugs that offset development costs.
Market segment marginality - Pharma neurology
Zevra Therapeutics is a biopharmaceutical company specializing in developing treatments for rare diseases of the central nervous system. This chart reflects its operational structure during the clinical development phase. It demonstrates the significant investment in research required to develop treatments for patients with unmet medical needs.
Market marginality as a whole
Zevra Therapeutics is a biopharmaceutical company specializing in developing treatments for rare diseases, particularly in neuroscience. Its future profitability depends on the success of its clinical programs. This overall market profitability chart contrasts with the niche rare disease market, where high unmet need can provide significant pricing power for effective drugs.
Employees in the company, segment and market as a whole
Number of employees in the company Zevra Therapeutics
Zevra Therapeutics is a biopharmaceutical company specializing in developing treatments for rare diseases, primarily in neuroscience. This chart shows a small team of scientists and clinicians. The size of the team reflects a focused strategy of developing drugs for niche markets with unmet medical needs.
Share of the company's employees Zevra Therapeutics within the market segment - Pharma neurology
This figure reflects Zevra Therapeutics' strategy for treating rare diseases. The company's pharmaceutical workforce is focused on the development and commercialization of drugs for rare diseases of the central nervous system. This team is working in a niche with a high unmet medical need, which can provide a faster path to approval.
Number of employees in the market segment - Pharma neurology
Zevra Therapeutics is a biopharmaceutical company specializing in developing treatments for rare diseases, particularly in neuroscience. Working with orphan diseases requires unique scientific expertise and close collaboration with patient communities. This graph illustrates the growth of specialty pharmaceuticals driven by scientific breakthroughs.
Number of employees in the market as a whole
Zevra Therapeutics, Inc. specializes in rare diseases. Its business model is based on developing and commercializing drugs for small patient populations. The company's success depends on regulatory approvals, not the economic cycles shown in this chart.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Zevra Therapeutics (ZVRA)
Zevra Therapeutics is a pharmaceutical company specializing in rare diseases. This chart shows the valuation of a biotech company with approved products. The moderately high market capitalization per employee reflects the balance between the value of intellectual property and the need to maintain a commercial sales and marketing team.
%20of%20the%20company%20Zevra%20Therapeutics%20(ZVRA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Zevra-Therapeutics-ZVRA&v=1772661066097 "Chart of market capitalization per employee (in thousands of dollars) of the company Zevra Therapeutics (ZVRA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma neurology
Zevra Therapeutics specializes in developing treatments for rare diseases, particularly in neuroscience. Like many biotech companies, its value is locked into its pipeline. This chart shows the investors' hopes for scientific developments that could generate huge profits in the future.
%20by%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-neurology&v=1772661066112 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma neurology")
Market capitalization per employee (in thousands of dollars) for the overall market
Zevra Therapeutics is a biopharmaceutical company specializing in rare diseases. This chart shows a high valuation per employee, which is typical for this sector. The company's value is determined by its pipeline of drug candidates and its ability to successfully complete clinical trials to bring these products to market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772661066119 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Zevra Therapeutics (ZVRA)
Zevra Therapeutics is a biopharmaceutical company specializing in rare (orphan) diseases, primarily in the central nervous system. The company has approved products. This chart shows how profitable this niche strategy is. Revenue per employee depends on the price of these rare drugs and the R&D team's ability to expand the portfolio.
%20Chart%20Zevra%20Therapeutics%20(ZVRA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Zevra-Therapeutics-ZVRA&v=1772661066121 "Company Profit Per Employee (in thousands of dollars) Chart Zevra Therapeutics (ZVRA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma neurology
Zevra Therapeutics is a biotech company specializing in rare diseases, particularly neuroscience. This chart shows the loss per employee during the development phase. It serves as a benchmark for assessing how intensively the company invests in its scientists to advance drug candidates, where R&D costs are high and the potential return, if successful, is enormous.
%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-neurology&v=1772661066123 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma neurology")
Profit per employee (in thousands of dollars) for the market as a whole
Zevra Therapeutics (ZVRA) is a company specializing in rare (orphan) diseases, specifically drugs for sleep disorders and neurological disorders. It's a biotech company on the verge of commercialization. This graph reflects the transition from R&D (losses per employee) to sales. If their drugs are approved and enter the market, this metric should skyrocket, as orphan drugs are very expensive.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772661066134 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Zevra Therapeutics (ZVRA)
Zevra Therapeutics is a biopharmaceutical company specializing in developing drugs for rare diseases. This chart reflects the company's activities in the commercialization and development stages. Revenue per employee is dependent on the success of existing products and progress in clinical trials for new ones.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Zevra-Therapeutics-ZVRA&v=1772661066155 "Sales chart per company employee Zevra Therapeutics (ZVRA)")
Sales per employee in the market segment - Pharma neurology
Zevra Therapeutics is a pharmaceutical company specializing in the treatment of rare diseases, particularly in neurology. This chart shows the average revenue per employee in this segment. It serves as a comparison to the sector, where productivity often depends on the success of R&D and the commercialization of niche drugs.
Sales per employee for the market as a whole
Zevra Therapeutics is a biopharmaceutical company specializing in rare (orphan) diseases, primarily in neurology. They have both approved products and development pipelines. This metric reflects how their small, focused team (R&D and sales) generates revenue from sales of niche, high-priced drugs.
Short shares by company, segment and market as a whole
Shares shorted by company Zevra Therapeutics (ZVRA)
Zevra Therapeutics is a biopharmaceutical company specializing in rare diseases. The bearish sentiment seen in this chart reflects the risks associated with its key drug, Arimoclomol. Bears may doubt the drug will receive FDA approval or that its commercial potential justifies its current valuation.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Zevra-Therapeutics-ZVRA&v=1772661066276 "Short Shares Chart for the Company Zevra Therapeutics (ZVRA)")
Shares shorted by market segment - Pharma neurology
Zevra Therapeutics is a biotech company specializing in treating rare diseases, particularly in neuroscience. This chart reflects the overall sentiment in the sector. It reflects the high investor skepticism toward biotech companies operating in the orphan (rare) disease niche, where markets are small and R&D risks are high.
Shares shorted by the overall market
Zevra Therapeutics (ZVRA) focuses on rare neurological diseases. It's a biotech whose value is based almost entirely on expectations of future breakthroughs. This chart shows the general level of risk aversion. When pessimism runs high, investors are unwilling to fund "science" and abandon speculative stocks like ZVRA.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Zevra Therapeutics (ZVRA)
Zevra Therapeutics is a biotech company specializing in rare CNS diseases. This chart measures the level of speculative interest. It shows when the stock is "overheated" (overbought) on positive R&D news or "oversold" (bottomed out) amid a general cooling in the sector or setbacks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Zevra-Therapeutics-ZVRA&v=1772661066357 "RSI 14 indicator chart for the company's stock Zevra Therapeutics (ZVRA)")
RSI 14 Market Segment - Pharma neurology
Zevra Therapeutics is a biopharmaceutical company specializing in the treatment of rare diseases, primarily in neuroscience. Their strategy is to develop and commercialize drugs for niche markets. This chart reflects the overall sentiment in the biotech sector. It helps assess how the market views this speculative industry as a whole, and how Zevra compares to that.
RSI 14 for the overall market
Zevra Therapeutics (ZVRA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ZVRA (Zevra Therapeutics)
Zevra Therapeutics (ZVRA) is a pharmaceutical company specializing in rare diseases. Its flagship product, AZSTARYS (for ADHD), is also developing sleep medications. This chart shows the average 12-month Wall Street forecast. It reflects analysts' assessments of the commercial potential of AZSTARYS and the company's other drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ZVRA-Zevra-Therapeutics&v=1772661066384 "A chart showing analyst consensus forecasts for the expected stock price. ZVRA (Zevra Therapeutics)")
The difference between the consensus estimate and the actual stock price ZVRA (Zevra Therapeutics)
Zevra Therapeutics (ZVRA) is a biopharmaceutical company specializing in the treatment of rare CNS diseases (e.g., sleep disorders). This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the commercial potential analysts see in their portfolio of orphan (rare) disease drugs.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ZVRA-Zevra-Therapeutics&v=1772661066385 "A chart showing the difference between the consensus forecast and the actual stock price. ZVRA (Zevra Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma neurology
Zevra Therapeutics is a biotech company focused on orphan diseases, primarily in neurology. This chart shows analysts' overall expectations for the entire neurology sector. It reflects whether experts believe the R&D pipeline targeting rare CNS diseases will be commercially successful.
Analysts' consensus forecast for the overall market share price
Zevra Therapeutics is a biopharmaceutical company specializing in developing treatments for rare diseases, primarily in neuroscience. This chart shows overall risk appetite. For Zevra, as a clinical-stage company, overall market optimism is important for raising the capital needed to fund lengthy and expensive clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Zevra Therapeutics
Zevra (ZVRA) is a biopharmaceutical company focused on rare diseases, particularly in neurology. This chart represents an R&D bet. Its valuation reflects the market's faith in their scientific platform and their ability to bring their niche drugs to FDA approval, where (due to a lack of competition) they can be very expensive.
AKIMA Market Segment Index - Pharma neurology
Zevra (ZVRA) is a biotech focused on rare diseases; the company (an M&A aggregator) owns a portfolio of approved drugs for the treatment of rare CNS disorders. This summary metric evaluates R&D. The graph shows the average value for the segment. This benchmark: how does this niche commercial model (ZVRA) differentiate it from the average pharma company?
The AKIM Index for the overall market
Zevra Therapeutics is a rare disease company combining commercial products and R&D. Its focus is on sleep and metabolic disorders. This chart, which reflects the market average, provides a macro backdrop. It helps assess how Zevra, which is building a portfolio of orphan drugs, compares to overall economic trends.
